TY  - JOUR 
AU  - Clark, J.C.
AU  - Martin, E.M.
AU  - Morán, L.A.
AU  - Di, Y.
AU  - Wang, X.
AU  - Zuidscherwoude, M.
AU  - Brown, H.C.
AU  - Kavanagh, D.M.
AU  - Hummert, J.
AU  - Eble, J.A.
AU  - Nieswandt, B.
AU  - Stegner, D.
AU  - Pollitt, A.Y.
AU  - Herten, D.-P.
AU  - Tomlinson, M.G.
AU  - García Alonso, Ángel
AU  - Watson, S.P.
PY  - 2023
SN  - 2399-3642
UR  - http://hdl.handle.net/20.500.11940/21360
AB  - CLEC-2 is a target for a new class of antiplatelet agent. Clustering of CLEC-2 leads to phosphorylation of a cytosolic YxxL and binding of the tandem SH2 domains in Syk, crosslinking two receptors. We have raised 48 nanobodies to CLEC-2 and...
LA  - eng
KW  - Animals
KW  - Humans
KW  - Mice
KW  - Lectins, C-Type
KW  - Membrane Glycoproteins
KW  - Signal Transduction
KW  - Single-Domain Antibodies
KW  - Syk Kinase
TI  - Divalent nanobodies to platelet CLEC-2 can serve as agonists or antagonists
DO  - 10.1038/s42003-023-04766-6
T2  - Communications biology
M2  - 376
KW  - AS Santiago
KW  - IDIS
VL  - 6
ER  -